Because previous studies showed ligand-independent activation of AR transcription by EGF in prostate cancer cells (20–22), we first assessed the effects of EGF and a specific EGFR inhibitor PD168393 on AR transactivation in bladder cancer lines. Here, EGFR is linked to urinary bladder cancer.